Observational studyCancer chemotherapy and pharmacology2021

Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.

Kazuo Kobayashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.